PRT-060318 3HCl

体外活性：PRT318 通过 GPVI/FcRγ（一种 ITAM 受体复合物）抑制血小板活化，但不通过 ADP 或凝血酶（G 蛋白偶联受体）抑制血小板活化。 PRT318 在 BCR 触发后和护士样细胞共培养物中有效拮抗 CLL（慢性淋巴细胞白血病）细胞存活。 PRT318 在 BCR 触发后抑制 Syk 和细胞外信号调节激酶磷酸化。激酶测定：PRT-060318（也称为 PRT318）是一种新型、有效、选择性的 Syk 酪氨酸激酶抑制剂，可作为 HIT 治疗的一种方法。 PRT-060318 被鉴定为纯化 Syk 激酶的有效抑制剂。当在广泛的激酶酶测定中以 50 nM 浓度评估 PRT-060318 时，Syk 激酶被抑制 92%，而所有其他激酶的活性保留超过 70%。细胞测定：PRT-060318 被鉴定为纯化 Syk 激酶的有效抑制剂。当在广泛的激酶酶测定中以 50 nM 浓度评估 PRT-060318 时，Syk 激酶被抑制 92%，而所有其他激酶的活性保留超过 70%。此外，PRT-060318 可以剂量反应性抑制惊厥素诱导的人 PRP 聚集。此外，还发现 PRT-060318 能够剂量反应性抑制经 convulxin 处理的血小板中细胞内钙的增加。随着时间的推移，跟踪用不同剂量的 PRT318 处理的细胞数量。 PRT318 以剂量依赖性方式抑制敏感细胞系的生长。用指定剂量的 PRT318 处理两种敏感（LY7 和 LY18）和两种耐药（LY3 和 LY4）细胞系。

在兔和猪模型中，静脉输注 PRT060318 的目标是最大限度地抑制 Syk 激酶活性，并显着抑制动脉血栓形成。 PRT060318在猪体内的抗血栓活性非常显着，因为它完全抑制了CVXN诱导的血小板聚集，对ADP诱导的血小板聚集没有影响，并且不延长耳部出血时间。此外，Syk 抑制剂 PRT318 是 HIT 中的活性剂。使用口服生物有效的 PRT318 抑制 Syk 信号传导可限制 HIT IC 在体内的血小板减少和血栓形成作用。动物研究表明，与媒介物治疗的小鼠出现预期的血小板减少症相反，PRT-060318 治疗的小鼠在注射肝素后血小板计数没有显着变化。此外，发现 PRT-060318 治疗小鼠的最低血小板计数显着高于对照小鼠。 PRT-060318 治疗的小鼠没有表现出出血素质或其他不良反应。此外，PRT-060318 在挤压血栓形成模型中的治疗可显着抑制血小板沉积，而不会改变出血时间。

PRT-060318（也称为 PRT318）是一种新型、有效、选择性 Syk 酪氨酸激酶抑制剂，用于治疗 HIT。研究发现 PRT-060318 是纯 Syk 激酶的强抑制剂。当在多种激酶测试中以 50 nM 浓度评估 PRT-060318 时，Syk 激酶被抑制 92%，而所有其他激酶的活性保留了 70% 以上的活性。

---

PRT-060318（PRT318）结构和特异性[1]
通过高通量筛选化学文库，发现了一类新型Syk抑制剂。通过广泛的结构-活性关系研究和合成，优化了属于4-苯胺基-2-（2-氨基乙基氨基）嘧啶-5-甲酰胺类的化合物，以鉴定高效和特异的Syk抑制剂PRT-060318（PRT318），（2-（（1R，2S）-2-氨基环己基氨基）-4-（间甲苯基氨基）嘧啶-5-甲酰胺）（补充图1，可在Blood网站上获得；见在线文章顶部的补充材料链接）。PRT318，也称为P142-76，是嘧啶-5-甲酰胺的衍生物（美国专利号6432963）。[1]
使用激酶分析仪评估PRT318与Syk相互作用的分子特异性。通过测定Y352位Syk的磷酸化来研究PRT318的细胞内特异性，已知Y352位在DHL4 B细胞系（DSMZ）中由src家族酪氨酸激酶（SFTK）在B细胞受体下游磷酸化。在含有10%胎牛血清的RPMI中培养的细胞与PRT318预孵育1小时，然后在37°C下用5μg/mL抗-Ig激活30分钟。通过离心将细胞制成颗粒，并在蛋白酶和磷酸酶抑制剂（完全蛋白酶抑制剂鸡尾酒，PhosSTOP，Roche Diagnostics）存在下裂解。裂解物经过十二烷基硫酸钠聚丙烯酰胺凝胶电泳，并转移到硝化纤维膜上。用兔抗磷酸SYK（Y352）检测印迹。

---

血小板中的PRT-060318（PRT318）活性[1]
评估了PRT318在几种不同激动剂存在下对体外血小板聚集的活性。人富血小板血浆（PRP）由签署知情同意书后从健康供体获得的正常人血液制备。在96孔格式的测定中进行了PRP的聚集，以比较PRT318对康夫新和二磷酸腺苷（ADP）的影响。Convulxin是一种糖蛋白VI（GPVI）激动剂，其最终浓度如图所示。ADP来自Chronolog。在96孔格式的测定中测量了人血小板钙通量，以比较康夫新刺激后PRT318与PAR1激动剂TRAP-6的效果。 为了评估PRT-060318（PRT318）在HIT IC刺激后抑制血小板聚集的能力，我们首先在有利于形成超大复合物的条件下制备了肝素-PF4复合物。17简而言之，重组人PF4和肝素以1.5:1的摩尔比混合，并在37°C下孵育1小时。将含有5μg hPF4的超大复合混合物的等分试样（5μL）加入PRP中，在37°C下搅拌下与PRT318（0-3μM）一起孵育15分钟，最终体积为250μL。通过加入KKO（一种单克隆HIT样抗体18，终浓度为80μg/mL）引发聚集。记录了最终的聚合百分比。

---

SRA[1]
我们使用血清素释放试验（SRA）研究了PRT-060318（PRT318）在人HIT血清存在的情况下对血小板活化的影响。SRA是确认血小板活化HIT抗体的金标准。简而言之，洗涤后的14C-血清素负载血小板与PRT318在1.0μM下孵育，然后在室温下与0.1或100IU/mL肝素和HIT血清孵育1小时。阳性对照血小板仅用赋形剂处理。通过离心去除血小板，并通过闪烁计数测量上清液中释放的14C-血清素。测定上清液中14C-血清素相对于标记血小板中总14C-血清素的百分比。19阳性结果是在0.1 IU/mL肝素浓度下释放的血清素超过20%，在100 IU/mL的肝素浓度下低于20%。

随着时间的推移，监测用不同 PRT318 剂量处理的细胞数量。 PRT318 剂量依赖性地抑制敏感细胞系的生长。 PRT318 的推荐剂量适用于两种敏感（LY7 和 LY18）和两种耐药（LY3 和 LY4）细胞系。

---

NLC共培养中CLL细胞的凋亡[2]
通过将CLL患者的PBMC悬浮在含有10%胎牛血清和青霉素-链霉素-谷氨酰胺的完全RPMI培养基中，使其浓度达到107个细胞/mL（共2mL），建立NLC共培养。如前所述，细胞在24孔板中孵育14天（23）。为了评估Syk抑制剂PRT-060318（PRT318）和P505-15是否可以克服NLC的保护作用，CLL细胞在标准化条件下在NLC上或悬浮液中培养，有无PRT318和P505-15。在指定的时间点，收集CLL细胞，并如前所述测定细胞活力。

---

酶联免疫吸附试验（ELISA）[2]
为了评估Syk抑制剂PRT-060318 (PRT318)和P505-15在用抗IgM（10mg/mL）或NLC刺激CLL细胞后对CCL3和CCL4分泌的影响，如前所述，在活化的CLL细胞的上清液中测量趋化因子水平。在抗IgM或NLC共培养24小时后，收集上清液，并根据制造商的说明通过定量ELISA检测CCL3、CCL4和CXCL13（仅在NLC共文化中）。

---

趋化性测定[2]
为了评估PRT-060318（PRT318）和P505-15对CLL细胞趋化性的影响，我们如上所述对聚碳酸酯Transwell插入物进行了趋化性测定。简而言之，CLL细胞（107/mL）在37°C、5%CO2、10μg/mL抗-IgM的完全RPMI培养基中孵育，该培养基含有或不含有2μM PRT318和P505-15。1小时后，将CLL细胞离心并重新悬浮在含有0.5%牛血清白蛋白的RPMI 1640中，浓度为107个细胞/mL。将100μL细胞悬浮液加入直径为6.5 mm、孔径为2μm的Transwell培养插入物的顶部腔室中。然后将过滤器转移到含有或不含有200 ng/mL CXCL12或1μg/mL CXCL13的培养基的孔中。将腔室在37°C的5%CO2中孵育3小时。孵育后，将下腔室中的细胞悬浮并分成等分，用FACSCalibur以60μL/min的速度计数20秒，一式两份。在相同条件下计数1/20稀释的输入细胞。

---

CLL细胞在基质细胞下的迁移（假性脾炎）[2]
为了确定Syk抑制剂PRT-060318（PRT318）和P505-15对CLL细胞在基质细胞下自发迁移的影响，我们如前所述定量了伪脾炎。简而言之，在试验前一天，将小鼠基质细胞（9-15C和TSt-4）以1.8×105个细胞/孔的浓度接种到补充有10%胎牛血清和青霉素-链霉素-谷氨酰胺的RPMI 1640中的胶原蛋白包被的12孔板上。在添加10μg/mL的抗-IgM之前，将浓度为107/mL的CLL细胞在37°C下在添加或不添加2μM PRT318或P505-15的完全培养基中的5%CO2中孵育30分钟。再孵育1小时后，将CLL细胞加入基质细胞层，并在37°C的5%CO2中孵育4小时。通过用RPMI培养基剧烈洗涤3次，去除未迁移到基质细胞层的细胞。

Studies in vivo [1]
C57Bl/6 (Charles River Labs) mice were used for the dose selection study. The transgenic HIT mice used to determine the effect of PRT-060318 (PRT318) on HIT IC-induced thrombocytopenia are homozygous for both FcγRIIA and human PF4 and null for mouse PF4.8,20 [1]
To determine the effect of PRT-060318 (PRT318) on HIT IC-induced thrombocytopenia and thrombosis, HIT model mice were treated with KKO (20 mg/kg body weight, intraperitoneally) on day 0. The mice were divided into sex- and weight-matched experimental and control groups. On days 1 to 7, experimental mice (n = 6) received PRT318 (30 mg/kg body weight) orally via gavage twice a day, whereas control mice (n = 6) received vehicle only (sterile water). Both groups received heparin (1600 U/kg body weight, subcutaneously) once daily. Mice were anesthetized by isoflurane inhalation for injections and blood collections. Blood was collected via the retro-orbital plexus using 50 μL ethylenediaminetetraacetic acid-coated microcapillary tubes (Microcaps, Drummond Scientific). Blood was collected 3 days before the antibody injections for baseline values and then on days 1 through 7 after antibody injections. Platelet counts were measured using a Hemavet Analyzer (model 850, CDC Technologies) and monitored over time to assess thrombocytopenia. Mouse plasma samples, collected 2 hours after PRT318 dosing, were precipitated with acetonitrile, and concentrations of PRT318 were quantified by liquid chromatography/tandem mass spectrometry. [1]
To evaluate the effect of PRT-060318 (PRT318) treatment on thrombosis in vivo, the protocol was modified as follows to take advantage of a novel thrombosis visualization technology. Experimental (n = 3) and control (n = 3) HIT mice were injected with KKO and PRT318 or vehicle only as described in the previous paragraph. For the imaging method, blood was collected in heparin from the retro-orbital plexus of untreated syngeneic donor mice. The donor platelets were washed, pooled, and incubated at 37°C for 10 minutes with Alexa750-labeled anti-GPIX antibody. The labeled platelets were pelleted and resuspended in sterile saline. Both experimental and control mice were infused with 1 × 108 labeled platelets in 100 μL aliquots via the retro-orbital plexus. All mice were then injected with heparin as described in the previous paragraph. Mice were killed 3 hours after heparin treatment, and their organs were perfused with sterile phosphate-buffered saline. Lungs were excised, fixed in 7% paraformaldehyde, and imaged with an Odyssey Imaging System (LI-COR Biosciences). The images were evaluated using Nikon NIS Elements image analysis software Version 3.10 (NIS-Elements, Advanced Research). Thrombi were identified as areas with fluorescence intensity at least 1.5 times above background. The Thrombosis Score represents the number of thrombi multiplied by the average intensity.

---

Mice: On day 0, KKO (20 mg/kg body weight, intraperitoneally) is administered to mice in the Heparin-induced thrombocytopenia (HIT) model. A sex- and weight-matched experimental group and a control group are created from the mice. Days 1 through 7 see the oral gavage of PRT318 (30 mg/kg body weight) to six experimental mice (n = 6), while days 8 through 14 see the oral administration of vehicle alone (sterile water) to six control mice (n = 6). Subcutaneous heparin (1600 U/kg body weight) is administered once daily to both groups. To make injections and blood collections easier on the mice, isoflurane is inhaled.

---

30 mg/kg; i.p.

Mice, rabbit, pig models

[1]. Blood. 2011 Feb 17; 117(7): 2241–2246.

[2]. Leukemia. 2012 Jul;26(7):1576-83.

Our studies document that inhibition of Syk signaling with the orally bio-available PRT318 limits the thrombocytopenic and thrombotic effects of HIT IC in vivo. We focused on the effects of inhibition of Syk in platelets. Similar effects on monocytes and endothelial cells cannot be ruled out yet are probably beneficial with regards to pathology of HIT. It is of note that the antithrombotic effects were readily visualized with a new technique, applicable to other forms of immune thrombocytopenia/thrombosis disorders, (M.S. and W.B., unpublished observations, March 2010). Taken together, these studies clearly demonstrate that the Syk inhibitor PRT318 is an active agent in HIT. These results support the hypothesis that inhibition of FcγRIIA-Syk signaling with PRT318 or related compounds may have beneficial effects in the treatment of human HIT. Future studies will be needed to address planned short-term use, effects on other Syk-expressing cells, and on hemostasis.[1]

---

Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is involved in BCR-independent functions, such as B-cell migration and adhesion. In chronic lymphocytic leukemia (CLL), Syk becomes activated by external signals from the tissue microenvironment, and was targeted in a first clinical trial with R788 (fostamatinib), a relatively nonspecific Syk inhibitor. Here, we characterize the activity of two novel, highly selective Syk inhibitors, PRT318 and P505-15, in assays that model CLL interactions with the microenvironment. PRT318 and P505-15 effectively antagonize CLL cell survival after BCR triggering and in nurse-like cell-co-cultures. Moreover, they inhibit BCR-dependent secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell migration toward the tissue homing chemokines CXCL12, CXCL13, and beneath stromal cells. PRT318 and P505-15 furthermore inhibit Syk and extracellular signal-regulated kinase phosphorylation after BCR triggering. These findings demonstrate that the selective Syk inhibitors PRT318 and P505-15 are highly effective for inhibition of CLL survival and tissue homing circuits, and support the therapeutic development of these agents in patients with CLL, other B-cell malignancies and autoimmune disorders.[2]

C18H26CL2N6O

413.3446

340.201

1194961-19-7

11493841

Light yellow to yellow solid powder

1.3±0.1 g/cm3

602.1±65.0 °C at 760 mmHg

317.9±34.3 °C

0.0±1.7 mmHg at 25°C

1.672

1.62

118.95

4

6

5

25

447

2

CC1=CC(=CC=C1)NC2=NC(=NC=C2C(=O)N)N[C@@H]3CCCC[C@@H]3N

NZNTWOVDIXCHHS-LSDHHAIUSA-N

InChI=1S/C18H24N6O/c1-11-5-4-6-12(9-11)22-17-13(16(20)25)10-21-18(24-17)23-15-8-3-2-7-14(15)19/h4-6,9-10,14-15H,2-3,7-8,19H2,1H3,(H2,20,25)(H2,21,22,23,24)/t14-,15+/m0/s1

2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-(3-methylanilino)pyrimidine-5-carboxamide

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

配方 1 中的溶解度: 25 mg/mL (73.44 mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。